Oxaltie Injection 100mg

Oxaltie 100mg Injection by Ferozsons Laboratories contains Oxaliplatin, a third generation platinum based chemotherapy medicine. It is the standard adult vial size for FOLFOX chemotherapy in advanced colorectal cancer and adjuvant colon cancer therapy.

Oxaltie 100mg Ingredients and Usage

Oxaltie 100mg Injection contains Oxaliplatin as its active ingredient, a third generation platinum based antineoplastic medicine. Oxaliplatin features a platinum atom complexed with 1,2 diaminocyclohexane (DACH) and an oxalate group as its leaving ligand. Oncologists prescribe Oxaltie 100mg as the standard adult vial size for several gastrointestinal cancers.

Oxaltie 100mg treats advanced or metastatic colorectal cancer as part of the FOLFOX chemotherapy regimen combined with 5 fluorouracil and leucovorin. It also serves as adjuvant therapy after complete surgical resection of stage III colon cancer for up to 12 cycles.

Doctors also use Oxaltie 100mg off label for gastric, oesophageal, pancreatic, and biliary cancers under specialist supervision. The 100mg vial covers most adult body surface area requirements at the standard 85 mg per square metre dose in FOLFOX every 2 weeks.

How Does Oxaltie 100mg Work?

Oxaltie 100mg works by forming platinum DNA adducts inside cancer cells after intravenous infusion. The platinum atom binds covalently to the DNA double helix and creates intra strand and inter strand cross links. These cross links physically distort the DNA structure and block its normal function.

The damaged DNA cannot replicate or transcribe properly, halting cancer cell division. The DACH carrier group gives oxaliplatin a different binding profile from cisplatin and carboplatin, so it works in tumours resistant to those drugs.

Cells that cannot repair the platinum DNA damage eventually undergo apoptosis, or programmed cell death. This selective effect on rapidly dividing cells underpins oxaliplatin's activity in colorectal cancer.

Oxaltie 100mg Side Effects

Oxaltie 100mg can cause significant side effects, with peripheral neuropathy being the most distinctive and often dose limiting. The oncology team monitors blood counts, kidney function, and neurological symptoms before every cycle.

• Acute cold induced peripheral neuropathy with tingling or numbness in hands, feet, or throat triggered by cold drinks or air

• Chronic cumulative peripheral sensory neuropathy that may persist after treatment ends

• Nausea and vomiting, often requiring strong antiemetics

• Diarrhoea, which can be severe

• Bone marrow suppression including neutropenia, thrombocytopenia, and anaemia

• Fatigue and weakness (asthenia)

• Loss of appetite and weight loss

• Mouth sores (stomatitis) and mucositis

• Raised liver enzymes including AST, ALT, and bilirubin

• Skin reactions, hair thinning, and injection site irritation

• Fever and infections from low white cell counts

• Pharyngolaryngeal dysaesthesia (cold triggered throat discomfort with breathing or swallowing difficulty)

• Serious: anaphylaxis, pulmonary fibrosis, hepatic sinusoidal obstruction syndrome, posterior reversible encephalopathy syndrome (PRES), and rhabdomyolysis

Warnings

• Oxaltie 100mg carries a boxed warning for anaphylactic like reactions that can occur within minutes of infusion and during any cycle.

• Only specialised oncology units should administer Oxaltie under the supervision of a qualified chemotherapy physician.

• Patients must avoid cold drinks, cold air, and cold objects during infusion and for 1 to 2 days afterwards to reduce acute neuropathy.

• Hypersensitivity reactions tend to increase with cumulative doses, so monitor patients closely from cycle 6 onwards.

• Oxaltie is contraindicated in patients with a history of hypersensitivity to oxaliplatin or any other platinum based drug.

• Dilute Oxaltie 100mg only in 5% dextrose solution, as sodium chloride causes precipitation of the active ingredient.

• Never use aluminium needles or infusion equipment, as oxaliplatin reacts with aluminium and forms a black precipitate.

• Patients with severe renal impairment require dose adjustment due to reduced platinum clearance.

• Cumulative neurotoxicity may require dose reduction or treatment discontinuation if functional impairment develops.

• Inform your oncologist of any breathing problems, as Oxaltie can rarely cause pulmonary fibrosis or interstitial lung disease.

• Stop Oxaltie and seek urgent care for unexplained shortness of breath, dry cough, or fever during treatment.

• Oxaltie causes fetal harm and is contraindicated during pregnancy and breastfeeding.

• Women of childbearing potential and male partners must use effective contraception during treatment and for several months afterwards.

• Avoid live vaccines during Oxaltie therapy due to the risk of severe infection in immunocompromised patients.

• Stop Oxaltie and seek emergency care for signs of anaphylaxis, severe shortness of breath, seizures, or sudden vision changes.

Oxaltie 100mg Storage Conditions

Store Oxaltie 100mg vials at a temperature below 25°C in the original carton to protect the solution from light. Do not freeze the product, and use the prepared 5% dextrose infusion solution within 24 hours when refrigerated or 6 hours at room temperature. Always store Oxaltie 100mg out of the reach and sight of children at the dispensing pharmacy or hospital cytotoxic storage facility.